BE664500A - - Google Patents
Info
- Publication number
- BE664500A BE664500A BE664500DA BE664500A BE 664500 A BE664500 A BE 664500A BE 664500D A BE664500D A BE 664500DA BE 664500 A BE664500 A BE 664500A
- Authority
- BE
- Belgium
- Prior art keywords
- carnitine
- solution
- chloride
- pure
- nitrile chloride
- Prior art date
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 8
- 229960004203 carnitine Drugs 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- -1 chlorine ions Chemical class 0.000 claims description 6
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- 235000019270 ammonium chloride Nutrition 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- ZOYKKWXSDFNANU-UHFFFAOYSA-M (3-cyano-2-hydroxypropyl)-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)CC#N ZOYKKWXSDFNANU-UHFFFAOYSA-M 0.000 claims description 3
- 229910001923 silver oxide Inorganic materials 0.000 claims description 3
- PHIQHXFUZVPYII-LURJTMIESA-N (S)-carnitine Chemical compound C[N+](C)(C)C[C@@H](O)CC([O-])=O PHIQHXFUZVPYII-LURJTMIESA-N 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical group C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 4
- 229960003237 betaine Drugs 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 229960001518 levocarnitine Drugs 0.000 description 3
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 101100455063 Caenorhabditis elegans lmp-1 gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- PHIQHXFUZVPYII-UHFFFAOYSA-N carnitine Chemical compound C[N+](C)(C)CC(O)CC([O-])=O PHIQHXFUZVPYII-UHFFFAOYSA-N 0.000 description 1
- 229960000678 carnitine chloride Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE664500A true BE664500A (en)) |
Family
ID=207651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE664500D BE664500A (en)) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE664500A (en)) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2209545A1 (en)) * | 1972-12-07 | 1974-07-05 | Otsuka Pharma Co Ltd | |
| EP0623588A1 (en) * | 1993-04-08 | 1994-11-09 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Improved process for manufacturing L-(-)-carnitine from waste products having opposite configuration |
-
0
- BE BE664500D patent/BE664500A/fr unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2209545A1 (en)) * | 1972-12-07 | 1974-07-05 | Otsuka Pharma Co Ltd | |
| EP0623588A1 (en) * | 1993-04-08 | 1994-11-09 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Improved process for manufacturing L-(-)-carnitine from waste products having opposite configuration |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5750572A (en) | Salts of a polyunsaturated fatty acid and pharmaceutical formulations containing them | |
| EP0233106B1 (fr) | (-)-Benzhydrylsulfinylacétamide, procédé de préparation et utilisation en thérapeutique | |
| RU2128160C1 (ru) | Трометаминная соль (+)-(s)-2-(3-бензоилфенил)пропионовой кислоты, способ ее получения, фармацевтическая композиция | |
| US20080114187A1 (en) | Formoterol tartrate process and polymorph | |
| JP2010159292A (ja) | イミダゾリル化合物の塩酸塩一水和物 | |
| EP0755398B1 (en) | Process for the resolution of etodolac using glucamine derivatives | |
| AU2002349914A1 (en) | Formoterol tartrate process and polymorph | |
| BE664500A (en)) | ||
| FR2529545A1 (fr) | Nouveaux sels de carnitine ainsi que leur procede de preparation | |
| CA2147329C (fr) | Procede de preparation d'acide l-aspartique a partir d'aspartate d'ammonium | |
| FR2571366A1 (fr) | Procede de preparation de la l-carnitine et de ses sels | |
| US3468937A (en) | Process for the preparation of pure carnitine in betaine form | |
| ES2284078T3 (es) | Procedimiento para la redisolucion de nefopam. | |
| FI93725C (fi) | Menetelmä optisesti aktiivisten, oikealle kiertävien okso-isoindolinyylijohdannaisten valmistamiseksi | |
| JPH11228512A (ja) | Ｄ−アロイソロイシンの製造方法および製造の中間体 | |
| EP0023178B1 (fr) | Procédé de préparation de solutions concentrées d'amygdaline sous sa forme naturelle | |
| EP0626372A1 (fr) | 2-Hydroxy-3-(1-(1H-imidazol-4-yl)alkyl)-benzènecarboximidamides pour le traitement du glaucome | |
| CN112239442A (zh) | 二羟基二甲基异色满-3-甲酰-Phe,其制备,抗缺血性中风作用和应用 | |
| BE441861A (en)) | ||
| RU2220949C1 (ru) | Способ очистки этамбутола | |
| EP0251904A1 (fr) | Procédé de préparation du maléate acide de lévomépromazine | |
| FR2462426A1 (fr) | Nouveau derive de la 2-(1-naphtyl)piperidine, sa preparation et son application comme medicament | |
| FR2471366A1 (fr) | Procede nouveau pour la preparation d'esters, d'amides, et d'acides aliphatiques a-amines-monofluores tels que la fluoroalanine, l'acide amino-2 fluoro-3 butyrique et leurs esters et amides derives | |
| BE903568A (fr) | Nouveaux composes chimiques a activites antiphlogistiques, antiseptiques et detergentes | |
| JPH0312051B2 (en)) |